Early T-cell precursor (ETP) leukaemias have been recently recognized as a form of T-cell acute lymphoblastic leukaemia (T-ALL) with a poor prognosis. The purpose of this review is to outline the most recent advances in the biology, genetics and prognostic significance of this aggressive disease.
INTRODUCTION T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematologic tumour resulting from the malignant transformation of T-cell progenitors [1] . As such, intrathymic T-cell development constitutes the pathophysiological framework underlying much of the basic mechanisms involved in the pathogenesis of T-ALL and a key conceptual background for understanding the biological heterogeneity of this disease. Early immunophenotype-based classifications grouped T-ALLs on the basis of the expression of surface markers differentially expressed during T-cell development. Moreover, the introduction of microarray gene expression profiling analyses showed a marked relationship between the expression of T-ALL oncogenes activated by chromosomal translocations, gene expression signatures related to arrest at different stages of T-cell development, and immunophenotype and clinical outcome [2] . Recently, genetic studies have shed new light on the biology of early T-cell presursor (ETP) T-ALLs, a distinct disease entity associated with a poor prognosis and defined by a characteristic immunophenotype and a gene expression signature indicative of a very early arrest in T-cell development.
GENE EXPRESSION PROFILING STUDIES DEFINE A GROUP OF EARLY IMMATURE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIAS
Over the last decade, a number of microarray gene expression profiling studies have recognized early immature T-ALLs as a transcriptionally distinct group of leukaemias. Early on, supervised analysis of microarray data from paediatric T-ALLs based on the expression of T-ALL transcription factor oncogenes activated by chromosomal translocations identified a distinct group of T-ALLs with the highest levels of expression of the LYL1 oncogene and coexpression of LMO2 [2] . Notably, LYL1 tumours not only showed a gene expression signature distinct from leukaemias driven by TLX1 and TAL1 oncogenes but also showed a gene expression signature reflecting an early arrest in T-cell differentiation. In contrast, TLX1-positive tumours were more related to early cortical thymocytes and expressed high levels of CD1 genes, whereas TAL1-positive leukaemias showed transcriptional upregulation of CD3 and TCR genes corresponding with a late cortical thymocyte stage of development arrest. Consistently, immunophenotype analysis showed that transcriptionally defined LYL1 and LYL1-related T-ALLs universally expressed the early haematopoietic marker CD34 and myeloid antigens (CD13 or CD33) and for the most part lacked expression of both CD4 and CD8. In addition, and supporting a unique genetic basis for these leukaemias, transcriptionally defined LYL1 and LYL1-related T-ALLs showed a high prevalence of 5q, 13q and 11q chromosomal deletions and in contrast lacked deletions involving the short arm of chromosome 9, which delete the CDKN2A/B tumour suppressor gene in over 70% of all T-ALLs.
These results were subsequently validated and extended in independent series. First, unsupervised analyses of adult and paediatric T-ALLs identified an immature cluster with frequent expression of myeloid CD13 or CD33 surface antigens [3] . As before, these immature leukaemias strongly expressed LYL1 and CD34 genes and were highly related to the previously reported LYL1 group [3] . In addition and most notably, these immature leukaemias transcriptionally clustered with the most immature ETP and Pro-T subpopulations when compared with normal T-cell progenitors [3] . More recently, similar results have been reported in one of the largest microarray series analysed to date, which recognized an immature cluster of T-ALLs highly enriched for immature CD4 CD8 double-negative cases [4] . Consistent with previous studies, samples in this immature cluster expressed CD34, frequently coexpressed the myeloid markers CD13 and/or CD33, expressed high levels of LYL1 and overlapped with the LYL1-positive cluster originally defined by Homminga et al. [4] .
EARLY T-CELL PRECURSOR T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIAS AS AN IMMUNOPHENOTYPICALLY DEFINED GROUP OF T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA ASSOCIATED WITH A POOR PROGNOSIS
The relevance of the transcriptionally defined early immature group of T-ALLs was highlighted by initial indications that these leukaemias could be associated with a less favorable outcome. Thus, the original LYL1-positive group of paediatric T-ALLs showed a poor prognosis particularly when compared with the more favourable group of TLX1-positive leukaemias [2] . In addition, expression of ERG, an early immature gene, was associated with inferior relapse-free survival in adult T-ALL [5] . However, the poor prognosis associated with early immature leukaemias was best recognized in a group of immunophenotypically defined leukaemias characterized by the absence (<5% positive cells) of CD1a and CD8 expression, weak CD5 (<75% positive cells) and expression (>25% positive cells) of at least one or more of the following myeloid or stem cell markers: CD117, CD34, human leukocyte antigen (HLA)-DR, CD13, CD33, CD11b or CD65 [6] . In this study, leukaemias matching this immunophenotype were named ETP T-ALLs, as they were more closely related to early T-cell precursors than to more mature thymocyte populations when analysed by gene expression profiling. ETP T-ALLs accounted for about 12% of paediatric T-ALLs in this series and were associated with a very poor prognosis [6] . Thus, for T-ALLs treated in Total Therapy Studies XIII, XIV and XV at St. Jude Children's Research Hospital, ETP-ALL patients showed a significantly worse clinical response to the first phase of remission induction therapy as measured by minimal residual disease [6] , which ultimately translated into
KEY POINTS
ETP T-ALLs are an immunophenotypically distinct group of T-ALLs with a poor prognosis.
Early immature T-ALLs defined on the basis of gene expression signatures and ETP T-ALLs are transcriptionally related to haematopoietic stem cells and myeloid progenitors.
Genetically, ETP T-ALLs show mutations driving activation of growth factor receptors and RAS signalling and genetic lesions disrupting lymphoid and haematopoietic development and epigenetic regulation of gene expression.
Early immature T-ALLs show a high prevalence of mutations involving AML oncogenes and tumour suppressor genes together with a lower incidence of mutations in NOTCH1 signalling and deletions encompassing the CDKN2A/B tumour suppressor loci. a significantly worse outcome, with a 10-year overall survival of 19% for patients with ETP-ALL compared with 84% for all other T-ALLs [6] . In the same study, the strong association of ETP T-ALLs with a poor outcome was confirmed in an independent series of 100 consecutive patients treated in the ALL-2000 protocol of the Associazione Italiana Ematologica Oncologica Pediatrica (AIEOP). In this second cohort, ETP T-ALLs showed reduced 2-year overall and event-free survival rates, as well as an increased cumulative incidence of remission failure or haematological relapse [6] .
Several subsequent studies analysing the prognostic significance of immunophenotypically defined ETP T-ALLs have now confirmed these results. In this regard, ETP T-ALLs accounted for 5.5% of paediatric T-ALL patients treated in the Tokyo Children's Cancer Study Group Study L99-15, and showed an inferior response to early remission induction therapy and were associated with a worse prognosis (4-year event-free survival 40% in ETP T-ALLs vs. 70% in non-ETP cases) [7] . As in the study of Coustan-Smith et al. [6] , ETP-ALLs showed no significant differences in clinical features and the ETP immunophenotype was the strongest risk factor for relapse in univariate and multivariate analyses. For patients treated in Shangai Children's Medical Center studies XH-ALL-99 and SCMC-ALL-2005, patients with an ETP T-ALL immunophenotype accounted for 16% of all T-ALLs [8] . ETP T-ALL cases in these series had a significantly worse eventfree survival (EFS; 11.1% for ETP T-ALLs vs. 57.6% for non-ETP-ALLs); higher rates of relapse and remission failure (58.3% for ETP T-ALLs vs. 24.2% for non-ETP T-ALLs); and a worse overall survival (13.3% for ETP T-ALL vs. 64.7% for non-ETP T-ALL cases) [8] .
EARLY IMMATURE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIAS ENCOMPASS EARLY T-CELL PRECURSOR T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA AND RELATED 'CLOSE TO EARLY T-CELL PRECURSOR' LEUKAEMIAS
Cross-examination of gene sets associated with the ETP T-ALL defined by Coustan-Smith et al. [6] , the LYL1 leukaemias originally identified by Ferrando et al. [2] and the immature T-ALL clusters reported by Soulier et al. [3] and Homminga et al. [4] reveal that these are closely related groups. However, it seems that transcriptionally identified early immature T-ALLs encompass a broader group than the immunophenotypically defined ETP T-ALLs. Thus, the original report by Coustan-Smith et al. [6] showed four T-ALLs that clustered together with ETP T-ALLs in an unsupervised analysis of the gene expression even though they did not fulfil all immunophenotypic criteria for their classification as ETP T-ALLs. Of these, three had expression of CD5 (with absence of myeloid or stem cell markers in one case) and a fourth case showed a very high expression of surface CD3 and TCR gamma/delta [6] . Conversely, gene expression analysis of adult T-ALL patients identified a robust cluster of early immature leukaemias encompassing about 50% of T-ALLs [9 & ]. As in previous gene expression studies, this transcriptionally defined cluster of early immature leukaemias was highly related to the original LYL1 group identified by Ferrando et al. [2] and showed a characteristic immunophenotype with expression of early haematopoietic markers such as CD34 and CD133 and myeloid-associated antigens such as CD13, CD33 and CD11b [9 & ]. However, based on CD5 expression only a fraction of these leukaemias seem to fulfil the strict ETP immunophenotype criteria, as 34% of them showed complete absence of surface CD5 expression, 55% showed low levels of surface CD5 expression and 11% were strongly CD5 positive [9 & ].
ABSENCE OF BIALLELIC DELETION OF TCRG (ABD) AS A PROGNOSTIC MARKER IN T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
To date, it remains to be established whether the poor prognosis associated with immunophenotypically defined ETP T-ALLs would also apply to the broader group of early immature T-ALLs identified by gene expression profiling. However, the recent identification of absence of bilallelic TCRG deletion (ABD), a marker of developmental arrest at the earliest stages of thymocyte development, as a poor prognostic marker strongly associated with an unfavourable response to chemotherapy and induction failure in paediatric T-ALL suggests that the adverse prognosis of ETP T-ALLs might extend to other early immature T-ALL cases [10] . Thus, even though TCR loci deletions are significantly less frequent in ETP T-ALL [6] , and the majority of ABD patients possessed the ETP T-ALL gene expression signature [10] , only one out of eight ABD T-ALL patients in this study met the ETP T-ALL immunophenotype criteria [10] . These discrepant results may very well reflect, at least in part, the challenge to accurately assess the ETP T-ALL immunophenotype across different laboratories. As of today, the ETP T-ALL immunophenotype is the most validated prognostic marker for the identification of high-risk early immature T-ALLs. However, its implementation as a diagnostic tool is not trivial. Further studies will determine whether T-ALLs with ABD are broadly overlapping with immunophenotypically defined ETP-TALLs and the comparative sensitivity and specificity of these two markers for the identification of high-risk T-ALLs.
EARLY T-CELL PRECURSOR AND EARLY IMMATURE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA ARE TRANSCRIPTIONALLY RELATED TO HAEMATOPOIETIC STEM CELLS AND MYELOID PROGENITORS
ETP T-ALLs were originally defined as an immunophenotypically homogeneous group of leukaemias with gene expression signatures related to those of early immature T-cell precursors and distinct from those of more mature T-cell progenitors [6] . However, recent reanalysis of the gene expression signatures associated with immunophenotypically defined T-ALLs has shown that the gene expression programmes of these leukaemias are indeed most closely related to those of human haematopoietic stem cells and myeloid progenitors [11 && ]. Similarly, and more broadly, the early immature cluster of adult T-ALLs identified by Van Vlierberghe et al. [9 & ] showed a marked enrichment in haematopoietic stem cell and granulocyte monocyte/macrophage precursor gene sets.
THE GENETICS OF EARLY T-CELL PRECURSOR AND EARLY IMMATURE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
Several lines of evidence suggested a distinct genetic landscape for both transcriptionally defined early immature T-ALLs and the ETP T-ALLs. As mentioned before, the absence of chromosomal deletions encompassing the CDKN2A/B locus suggested early on that the original LYL1-positive group of early immature T-ALLs could be genetically distinct from most other T-ALLs [2] . In addition, the initial group of immunophenotypically defined ETP ALLs seemed to have increased genomic instability as evidenced by a higher number and size of genomic lesions in their karyotypes [6] . The first indication of a specific genetic lesion possibly associated with the pathogenesis of early immature leukaemias was the identification via 4C analysis of rare but recurrent rearrangements resulting in aberrantly high levels of expression of the MEF2C gene in this group [4] . MEF2C encodes an important transcriptional regulator of lymphoid development, which is expressed at high levels in very early pre-DN1 and DN1 thymocytes and whose expression dramatically drops beyond the DN2 stage of thymocyte development. Notably, and supporting a potential role as a master regulator of the early immature T-ALL transcriptional signature, MEF2C can directly induce the expression of LYL1, LMO2 and HHEX, three oncogenic transcription factors expressed at high levels in early immature leukaemias [4] .
Given the lack of a unifying lesion for ETP T-ALL and to define the genetic landscape of this highrisk leukaemia group, Zhang et al. . In addition, ETP T-ALLs frequently showed inactivating mutations in genes encoding key transcription factors involved in haematopoietic development, including GATA3, ETV6, RUNX1, IKZF1 and EP300 and in genes encoding histone modifiers such as EZH2, EED, SUZ12, SETD2 and EP300 [11 && ]. Interestingly, several ETP T-ALL cases showed multiple genomic rearrangements suggestive of genomic instability, which seemed to be associated with lesions in genes involved in DNA mismatch repair (MLH3 and MSH5) and nonhomologous end joining (DCLRE1C) [11 && ]. Finally, and in agreement with previous reports, biallelic deletion of TCRG and deletions in the short arm of chromosome 9 encompassing the CDKN2A/B tumour suppressor genes were less prevalent in ETP T-ALLs compared with non-ETP leukaemias in this series [11 && ]. In parallel and following the close relationship between early haematopoietic and myeloid gene expression signatures and the transcriptional programmes characteristic of early immature adult T-ALLs, Van Vlierberghe et al. [9 & ] tested the possibility that transcriptionally defined early immature T-ALLs could be genetically related to myeloid tumours. Consistent with this hypothesis, 50% of adult early immature T-ALLs showed mutations in myeloid-specific oncogenes and tumour suppressor genes, including IDH1, IDH2, DNMT3A, FLT3 and NRAS and a lower prevalence of prototypical T-ALL genetic alterations such as activating mutations in the IL7R gene and mutations in NOTCH1 and FBXW7 activating the NOTCH signalling pathway [9 & ]. These results highlighted the close relationship between early immature T-ALLs and acute myeloid leukaemias. However, and most notably, even 25% of early immature T-ALLs showed concurrence of a myeloid-specific gene alteration and a prototypical T-ALL mutation. These results suggest that early immature adult T-ALLs comprise a heterogeneous leukaemia category characterized by overlapping myeloid and T-lymphoid genetic alterations. In addition, this study also identified and functionally characterized mutations in the ETV6 tumour suppressor gene resulting in expression of truncated forms of ETV6 with dominant negative activity in almost 25% of early immature T-ALLs [9 & ]. Interestingly, rare but recurrent fusions of the ETV6 tumour suppressor gene with NCOA2 were previously identified in rare leukaemias harbouring both T-lymphoid and myeloid characteristics [12] and two cases harbouring an ETV6-INO80D fusion oncogene were identified in the genomic studies of Zhang et al. 
CONCLUSION
Early immature T-ALLs encompassing ETP T-ALLs and related 'close to' ETP tumours constitute a genetically heterogeneous group of leukaemias characterized by a gene expression signature most related to that of haematopoietic stem cells and myeloid progenitors. Prognostically, the ETP T-ALL immunophenotype and the absence of biallelic deletion of the TCRG locus are associated with a very poor prognosis in children. Early immature T-ALLs seem to be more prevalent in adults; however, there is limited information on the prognosis of these leukaemias in the context of adult T-ALL [13, 14] . Notably, and despite harbouring a distinct transcriptional signature, early immature T-ALLs seem to lack unifying genetic alterations and are characterized by a lower prevalence of NOTCH1-activating mutations, higher prevalence of mutations in myeloid oncogenes and tumour suppressor genes, and genetic disruption of key transcription factors involved in haematopoietic and lymphoid development. Two recent studies have reported a possible worse prognosis for immature adult T-ALL leukaemias harbouring mutations in RUNX1 and DNMT3A [14, 15] . Further dissection of this heterogeneous leukaemia group is needed to address the prognostic implications of specific immunophenotypes, transcriptional signatures and genetic alterations. Therapeutically, new chemotherapy regimens, perhaps including drugs active in myeloid tumours, validated in relevant animal models are urgently needed for the treatment of high-risk ETP T-ALLs. In addition, targeted therapies may be available in the near future for those leukaemias harbouring activating mutations in druggable factors and signalling pathways such as FLT3, JAK1, JAK3, IL7R and NOTCH1.
